Sign In
Buy GOSS
$0.188
-0.0119 (-5.94%)
At Close: Jun 03, 2026
What Makes Gossamer Bio (GOSS) a New Buy Stock
01:32pm, Tuesday, 08'th Nov 2022
Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
This little-known biopharma stock could rally 70%: Goldman Sachs
07:35pm, Thursday, 20'th Oct 2022 Invezz
Gossamer Bio Inc (NASDAQ: GOSS) is in the green on Thursday after a Goldman Sachs analyst said the stock is ready for another huge move to the upside. Gossamer Bio stock could rally to $22 On Thursday
What 5 Analyst Ratings Have To Say About Gossamer Bio
06:03pm, Thursday, 20'th Oct 2022 Benzinga
Analysts have provided the following ratings for Gossamer Bio (NASDAQ:GOSS) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
1
0
0
La
This little-known biopharma stock could rally 70%: Goldman Sachs
03:35pm, Thursday, 20'th Oct 2022
Gossamer Bio Inc (NASDAQ: GOSS) is in the green on Thursday after a Goldman Sachs analyst said the stock is ready for another huge move to the upside.
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022
02:03pm, Thursday, 20'th Oct 2022 Benzinga
Upgrades
According to Credit Suisse, the prior rating for Hudson Pacific Properties Inc (NYSE:HPP) was changed from Underperform to Neutral. Hudson Pacific Properties earned $0.51 in the second quarte
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022
02:04pm, Wednesday, 21'st Sep 2022 Benzinga
Upgrades
For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago
What 4 Analyst Ratings Have To Say About Gossamer Bio
07:39pm, Monday, 19'th Sep 2022 Benzinga
Within the last quarter, Gossamer Bio (NASDAQ:GOSS) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
4
0
0
0
Last 30
Where Gossamer Bio Stands With Analysts
05:08pm, Monday, 19'th Sep 2022 Benzinga
Within the last quarter, Gossamer Bio (NASDAQ:GOSS) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
4
0
0
0
Last 30
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2022
02:19pm, Monday, 19'th Sep 2022 Benzinga
Upgrades
According to Citigroup, the prior rating for Tricon Residential Inc (NYSE:TCN) was changed from Neutral to Buy. The current stock performance of Tricon Residential shows a 52-week-high of $17
Analyst Ratings for Gossamer Bio
01:54pm, Monday, 19'th Sep 2022 Benzinga
Gossamer Bio (NASDAQ:GOSS) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
4
0
0
0
Last 30D
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch
02:28pm, Wednesday, 20'th Jul 2022 Benzinga
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a l
AMC, GameStop stocks jump to multi-month intraday highs, then pull back
11:53am, Wednesday, 20'th Jul 2022 MarketWatch
Shares of both AMC Entertainment Holdings Inc. and GameStop Corp. rallied above apparent resistance levels, and reached multi-month highs in intraday trading, before pulling back.
Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy
04:00pm, Tuesday, 19'th Jul 2022 Zacks Investment Research
Does Gossamer Bio (GOSS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy
01:09pm, Tuesday, 19'th Jul 2022
Does Gossamer Bio (GOSS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 52% Upside in Gossamer Bio (GOSS): Can the Stock Really Move This High?
01:55pm, Monday, 18'th Jul 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in Gossamer Bio (GOSS). While the effectiveness of this highly sought-after metric is questionable, the p
